Dynasore: Noncompetitive Dynamin GTPase Inhibitor for Endocytosis Research

Executive Summary: Dynasore (SKU A1605, by APExBIO) is a cell-permeable, noncompetitive inhibitor of dynamin GTPase activity with an IC50 of 15 µM in vitro (APExBIO, product page). It targets dynamin1, dynamin2, and Drp1 to reversibly block dynamin-dependent endocytosis, including transferrin and synaptic vesicle uptake, in various mammalian cell models (Zheng et al. 2024). Dynasore is insoluble in water and ethanol, but soluble in DMSO at ≥16.12 mg/mL, making DMSO the preferred solvent for stock solutions. The compound is a gold-standard tool for dissecting vesicle trafficking and signal transduction pathways, with extensive validation in cancer and neurodegenerative disease models (see review). Proper handling and storage at -20°C ensure stability for months of experimental use.

Biological Rationale

Dynamin GTPases are essential for clathrin-mediated endocytosis, vesicle scission, and intracellular trafficking (Zheng et al. 2024). Dysregulated endocytic trafficking is implicated in cancer, neurodegeneration, and pathogen entry (related article). APExBIO's Dynasore specifically inhibits dynamin-mediated membrane fission, enabling selective perturbation of vesicle trafficking pathways without broad off-target effects. This specificity is critical for mechanistic studies in signal transduction and disease models. Endocytic regulation also controls the uptake of extracellular vesicles (EVs), which are increasingly recognized as mediators of tumor–microbiome interactions, such as Fusobacterium nucleatum EVs in colorectal cancer (Zheng et al. 2024).

Mechanism of Action of Dynasore

Dynasore inhibits dynamin1, dynamin2, and Drp1 GTPase activity by binding noncompetitively to the GTPase domain (APExBIO). The compound does not compete with GTP for binding, allowing it to block GTP hydrolysis even in the presence of excess GTP (in vitro conditions: 37°C, pH 7.4). In mammalian cells, this leads to rapid and reversible inhibition of endocytosis, with effects observed within minutes of application at 15–80 µM (protocol details). Dynasore does not permanently alter dynamin structure, and endocytic function typically recovers within 30–60 minutes after washout. The compound has no significant effect on unrelated GTPases or cellular ATPases at recommended concentrations.

Evidence & Benchmarks

• Dynasore blocks transferrin uptake in HL-1 and HeLa cells within 10–15 minutes at 80 µM (see Table 1, Zheng et al. 2024).
• Rapid, reversible inhibition of synaptic vesicle endocytosis has been demonstrated in primary neurons using 20 µM Dynasore (see Figure S4, protocol article).
• Dynasore exhibits no effect on clathrin-independent endocytosis in control experiments, confirming specificity for dynamin-dependent pathways (benchmark report).
• In cancer cell models, Dynasore treatment suppresses uptake of bacterial EVs, supporting its use in tumor–microbe interaction studies (Zheng et al. 2024).
• Solubility in DMSO is ≥16.12 mg/mL at 25°C, while the compound is insoluble in water and ethanol (APExBIO).

Applications, Limits & Misconceptions

Dynasore is broadly applied in studies of endocytosis, vesicle trafficking, signal transduction, and disease modeling (see strategic review). It is routinely used to probe synaptic vesicle cycling in neurons and to evaluate the impact of endocytic inhibition on cancer cell signaling. In colorectal cancer research, Dynasore blocks Fusobacterium nucleatum EV uptake, enabling dissection of microbiome–tumor crosstalk mechanisms (Zheng et al. 2024). Compared to alternative dynamin inhibitors, Dynasore offers rapid, reversible action with low cytotoxicity at recommended doses. For a comprehensive protocol and usage scenarios, see the Dynasore (A1605) product page from APExBIO.

Common Pitfalls or Misconceptions

• Dynasore does not inhibit clathrin-independent or dynamin-independent endocytosis routes (e.g., caveolin-mediated uptake).
• It is insoluble in water and ethanol; use only DMSO for stock solutions.
• Prolonged exposure (>2 hours) or high concentrations (>100 µM) may elicit off-target effects or cytotoxicity.
• Dynasore is for research use only and is not suitable for clinical or diagnostic applications.
• Effects are reversible; permanent inhibition of dynamin requires genetic manipulation, not chemical blockade.

For further clarity on these points, this article provides practical troubleshooting guidance, while the current dossier expands on specificity and recent disease-relevant findings.

Workflow Integration & Parameters

Prepare Dynasore stock solutions in DMSO at ≥16.12 mg/mL. Warm to 37°C or sonicate to achieve complete dissolution. Store aliquots at -20°C for up to several months (APExBIO). For cell-based assays, dilute stock solution to a final concentration (typically 15–80 µM) in culture medium immediately before use. Do not exceed 0.5% DMSO final concentration in cell assays. For reversible inhibition, wash cells thoroughly with fresh buffer after treatment; endocytic activity typically recovers within 30–60 minutes. Refer to this protocol article for a stepwise workflow and troubleshooting tips. This article supplements prior coverage by integrating recent benchmarks and clarifying solvent compatibility for maximal reproducibility.

Conclusion & Outlook

Dynasore (A1605) is an established, rigorously validated dynamin GTPase inhibitor from APExBIO for dissecting endocytic mechanisms and vesicle trafficking. It is particularly valuable in cancer and neurodegenerative disease research, where endocytic signaling is dysregulated. Ongoing studies leverage Dynasore to probe tumor–microbiome vesicle interactions, offering translational insights (Zheng et al. 2024). As new disease models emerge, Dynasore remains a cornerstone reagent for mechanistic and translational cell biology.